Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837197 | 0.84 | AHR (0.57) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL9651185 | 0.83 | PDE7A (0.42) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL20597241 | 0.80 | PDE7A (0.43) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL3484512 | 0.79 | DRD2 (0.51) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL20714433 | 0.75 | PDE7A (0.39) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL11526659 | 0.73 | AHR (0.46) | AHRCMA1CES1 | |
| SCHEMBL9524333 | 0.73 | DRD2 (0.52) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL9909635 | 0.72 | DRD2 (0.55) | AHRDRD2DRD1DRD4DRD5 | |
| SCHEMBL10712776 | 0.72 | AHR (0.53) | AHRCES1MAPK1 | |
| SCHEMBL20597588 | 0.72 | DRD2 (0.49) | DRD2DRD1DRD4DRD3PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | AHR 259/4885DRD2 1841/4885DRD1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.